IN2014DN08093A - - Google Patents

Info

Publication number
IN2014DN08093A
IN2014DN08093A IN8093DEN2014A IN2014DN08093A IN 2014DN08093 A IN2014DN08093 A IN 2014DN08093A IN 8093DEN2014 A IN8093DEN2014 A IN 8093DEN2014A IN 2014DN08093 A IN2014DN08093 A IN 2014DN08093A
Authority
IN
India
Prior art keywords
methods
compositions
immunostimulatory cell
cell compositions
activated immunostimulatory
Prior art date
Application number
Inventor
Irene Ginis
Alan Smith
Shani Adi Zuloff
Marina Bubis
Mitchell Shirvan
Original Assignee
Macrocure Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrocure Ltd filed Critical Macrocure Ltd
Publication of IN2014DN08093A publication Critical patent/IN2014DN08093A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Methods of making activated immunostimulatory cell compositions activated immunostimulatory cell compositions and methods of using those compositions to stimulate therapeutic immune responses to tumors are described.
IN8093DEN2014 2012-03-15 2013-03-13 IN2014DN08093A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261611202P 2012-03-15 2012-03-15
PCT/IB2013/000848 WO2013136182A1 (en) 2012-03-15 2013-03-13 Activated immunostimulatory cell composition and uses thereof

Publications (1)

Publication Number Publication Date
IN2014DN08093A true IN2014DN08093A (en) 2015-05-01

Family

ID=48326349

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8093DEN2014 IN2014DN08093A (en) 2012-03-15 2013-03-13

Country Status (8)

Country Link
US (1) US20150030635A1 (en)
EP (1) EP2825634A1 (en)
JP (1) JP2015516374A (en)
CA (1) CA2865553A1 (en)
IN (1) IN2014DN08093A (en)
MX (1) MX2014010958A (en)
RU (1) RU2014140792A (en)
WO (1) WO2013136182A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103209682A (en) 2010-09-09 2013-07-17 马克罗柯尔有限公司 Activated leukocyte conditioned supernatant and uses for wound healing
WO2016075542A1 (en) * 2014-11-11 2016-05-19 Macrocure, Ltd. Methods for extended storage of activated leukocyte compositions
EP3785729B1 (en) * 2015-09-02 2024-03-13 The Cleveland Clinic Foundation Ovarian cancer vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
US7935531B2 (en) 2000-02-22 2011-05-03 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
AU2002342151B2 (en) * 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
AU2003256912A1 (en) 2002-08-16 2004-03-03 Yeda Research And Development Co. Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
KR101131727B1 (en) 2004-06-11 2012-03-28 가톨릭대학교 산학협력단 DENDRITE CELLS TRANSDUCED WITH RECOMBINANT ADENOVIRUS AdVCEA WHICH GENERATE CEA-SPECIFIC CYTOTOXIC T LYMPHOCYTES, VACCINE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
EP1748067A1 (en) 2005-07-29 2007-01-31 Institut Pasteur Polynucleotides encoding MHC class I-restricted hTERT epitopes, analogues thereof or polyepitopes
DK1989224T3 (en) 2006-02-24 2011-02-14 Us Gov Health & Human Serv Immunogenic peptides and methods of use
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US8097242B2 (en) 2006-10-05 2012-01-17 The Board Of Trustees Of The University Of Arkansas Target CA125 peptides for cancer immunotherapy
RU2548741C2 (en) 2009-03-05 2015-04-20 Макрокьюэ, Лтд. Activated leukocyte composition
CN103209682A (en) * 2010-09-09 2013-07-17 马克罗柯尔有限公司 Activated leukocyte conditioned supernatant and uses for wound healing

Also Published As

Publication number Publication date
US20150030635A1 (en) 2015-01-29
WO2013136182A1 (en) 2013-09-19
JP2015516374A (en) 2015-06-11
MX2014010958A (en) 2015-11-18
CA2865553A1 (en) 2013-09-19
RU2014140792A (en) 2016-05-10
EP2825634A1 (en) 2015-01-21

Similar Documents

Publication Publication Date Title
TN2012000414A1 (en) Forms of rifaximin and uses thereof
MX2021001879A (en) Dosing combinations for reducing undesired humoral immune responses.
IN2012DN01920A (en)
MX349096B (en) Anti-pd-l1 antibodies and uses thereof.
MX2016008448A (en) Var2csa-drug conjugates.
IL242934B (en) Microbiota restoration therapy (mrt), compositions and methods of manufacture
EA201490381A1 (en) SYNTHETIC NANOSEAGES WHICH STIMULATE THE FORMATION OF HUMORAL IMMUNE RESPONSE AND IMMUNE RESPONSE MEDIATED BY CYTOTOXIC T-LYMPHOCYTES (CTL)
IN2014CN04251A (en)
EP4279579A3 (en) Methods and compositions for natural killer cells
ZA201601534B (en) Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
SG10201709552XA (en) Capsid-modified, raav3 vector compositions and uses in gene therapy of human liver cancer
MX366130B (en) Bivalent inhibitors of iap proteins and therapeutic methods using the same.
IL239453A0 (en) Compositions and methods for treatment of cancer using bacteria
MX366804B (en) R-spondin translocations and methods using the same.
IN2014DN11201A (en)
GB201106743D0 (en) Novel compounds
MY185016A (en) Progenitor cells of mesodermal lineage
IN2014DN06104A (en)
ZA201500099B (en) Radiation-curable ,stable nail gel compositions and methods of preparation and use
IN2014DN08093A (en)
IN2014DN08407A (en)
MX2013014420A (en) Gel compositions.
MX2013003859A (en) Picropodophyllin polymorphs b or c for use in cancer therapy.
SG11201504779YA (en) Methods and compositions relating to treatment of cancer
EP2838543A4 (en) Immunostimulatory compositions and methods of manufacture